Shots:

• Cyclica to receive up front and milestones on completion of specific objectives. Yuhan will leverage Cyclica’s AI integrated drug discovery platform- Ligand Design and Ligand Express in two separate R&D programs
• Yuhan enhance its drug development efforts by utilizing AI integrated drug discovery platform across multiple therapeutic areas to develop novel therapies targeting Yuhan’s R&D interest
• Cyclica’s Ligand Design and Ligand Express provides AI-augmented platform to design advanced lead-like molecules- minimizing unwanted off-target effects by providing a holistic understanding of its biology and structural pharmacogenomics

Click here to­ read full press release/ article | Ref: Business wire | Image: Cyclica